# Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

> **NCT05715931** · PHASE2 · RECRUITING · sponsor: **Yu jiren** · enrollment: 30 (estimated)

## Conditions studied

- Adenocarcinoma of the Stomach
- Adenocarcinoma of Esophagogastric Junction
- HER2-positive Gastric Cancer

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Trastuzumab
- **DRUG:** 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)

## Key facts

- **NCT ID:** NCT05715931
- **Lead sponsor:** Yu jiren
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-28
- **Primary completion:** 2025-03-01
- **Final completion:** 2028-03-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05715931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05715931, "Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05715931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*